AnPac Bio-Medical Science Co., Ltd. (ANPC)
AnPac Bio-Medical Science Co., Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lishui, CN. The stock last traded at $4.30, down 3.15% on the session, giving a market capitalisation of $27.0M. On trailing twelve-month figures it carries a trailing P/E of -0.53, a net margin of -860.2%. Its beta of 1.56 implies it has historically moved more than the broad market.
AnPac Bio-Medical Science Co., Ltd. is a biotechnology firm that specializes in developing and commercializing tests designed for the early detection and screening of various cancer types. These diagnostic tools leverage the company's unique Cancer Differentiation Analysis (CDA) technology and associated devices. AnPac Bio primarily provides these solutions to corporate entities and life insurance companies across the People's Republic of China. Additionally, the company extends its offerings to include comprehensive physical examination package services. AnPac Bio was established in 2010 and maintains its main operational base in Lishui, China.
AnPac Bio-Medical Science Co., Ltd. is most often compared with the following Healthcare names: